文献速递骨软组织肉瘤与黑色素瘤

帕博利珠单抗对比安慰剂辅助治疗已切除III期黑色素瘤(EORTC 1325-MG/KEYNOTE-054):双盲随机对照3期试验的长期健康相关生活质量结果

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2024-08-12

该双盲随机对照3期试验在已切除III期黑色素瘤患者中比较帕博利珠单抗与安慰剂的长期健康相关生活质量(HRQOL)。从基线至长期HRQOL的平均变化帕博利珠单抗组为-0.56,安慰剂组为1.63,组间差异为-2.19(95%CI -4.65至0.27,p=0.081)。结论认为辅助帕博利珠单抗对长期HRQOL无显著影响。

要点

  • 从基线至长期HRQOL的平均变化帕博利珠单抗组为-0.56,安慰剂组为1.63。
  • 组间差异为-2.19(95%CI -4.65至0.27,p=0.081)。
  • 所有其他量表差异均小于5分且无统计学显著性。

核心结论

  • 与安慰剂相比,辅助帕博利珠单抗对已切除III期黑色素瘤患者的长期HRQOL无显著影响。
  • 这些发现与先前关于疗效和HRQOL的结果一起,支持在该情况下使用帕博利珠单抗。

研究设计与样本

  • 该研究为双盲、随机、对照3期试验,比较辅助帕博利珠单抗与安慰剂。
  • 纳入年龄18岁及以上、既往未经治疗、已切除IIIA、IIIB或IIIC期皮肤黑色素瘤且东部肿瘤协作组体能状态评分为1或0的患者。
  • 患者来自23个国家的123个学术中心和社区医院。
  • 患者按1:1随机分配,采用最小化技术按分期和地理区域分层,接受每3周静脉注射200 mg帕博利珠单抗或安慰剂,最多18次剂量。
  • 长期HRQOL分析纳入有基线HRQOL评估且随机化后108周时存活的所有患者。

主要发现

  • 2015年8月26日至2016年11月14日期间,1019例患者被随机分配至帕博利珠单抗组(n=514)或安慰剂组(n=505)。
  • 基线HRQOL评估完成率超过90%(帕博利珠单抗组481例[94%],安慰剂组467例[92%]),基线后时间点完成率在60%至90%之间。
  • 在有基线HRQOL评估的患者中,365例(39%)为女性,583例(61%)为男性。
  • 从基线至长期HRQOL的平均变化帕博利珠单抗组为-0.56(95%CI -2.33至1.22),安慰剂组为1.63(95%CI -0.12至3.38)。
  • 两组间差异为-2.19(95%CI -4.65至0.27,p=0.081),所有其他量表差异均小于5分且无统计学显著性。

关键数值与推荐

  • 所有HRQOL量表的临床相关性阈值定义为平均变化5分。
  • 长期HRQOL包括随机化后108周至48个月之间每6个月一次的评估。

临床怎么用

  • 作者认为,这些发现与先前关于疗效和HRQOL的结果一起,支持在该情况下使用帕博利珠单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 study, adjuvant pembrolizumab improved recurrence-free survival and distant-metastasis-free survival in patients with resected stage III melanoma. Earlier results showed no effect of pembrolizumab on health-related quality of life (HRQOL). Little is known about HRQOL after completion of treatment with pembrolizumab, an important research area concerning patients who are likely to become long-term survivors. This study reports long-term HRQOL results. METHODS: This double-blind, randomised, controlled, phase 3 trial compared adjuvant pembrolizumab with placebo in patients aged 18 years or older with previously untreated stage IIIA, IIIB, or IIIC resected cutaneous melanoma and an Eastern Cooperative Oncology Group performance status score of 1 or 0, recruited from 123 academic centres and community hospitals in 23 countries. Patients were randomly assigned (1:1) with a minimisation technique stratified for stage and geographical region to receive 200 mg of intravenous pembrolizumab or placebo every 3 weeks for up to 18 doses. Investigators, patients, and those collecting or analysing data were masked to group assignment. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, measured with the EORTC Quality of Life Questionnaire-Core 30. All patients with a baseline HRQOL evaluation available who were alive 108 weeks from randomisation were included in this analysis of long-term HRQOL. Long-term HRQOL included assessments measured every 6 months between 108 weeks and 48 months after randomisation. The threshold of clinical relevance for all HRQOL scales used was an average change of 5 points. The trial is ongoing, recruitment is completed, and HRQOL data collection is finalised. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37. FINDINGS: Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were randomly assigned to pembrolizumab (n=514) or placebo (n=505). Completion of the HRQOL evaluation at baseline exceeded 90% (481 [94%] patients in the pembrolizumab group and 467 [92%] in the placebo group), and ranged between 60% and 90% for post-baseline timepoints. Among patients with a baseline HRQOL evaluation, 365 (39%) were female and 583 (61%) were male. The mean change from baseline to long-term HRQOL was -0·56 (95% CI -2·33 to 1·22) in the pembrolizumab group and 1·63 (-0·12 to 3·38) in the placebo group. The difference between the two groups was -2·19 (-4·65 to 0·27, p=0·081). Differences for all other scales were smaller than 5 and not statistically significant. INTERPRETATION: Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL compared with placebo in patients with resected stage III melanoma. These findings, together with earlier results on efficacy and HRQOL, support the use of pembrolizumab in this setting. FUNDING: Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bührer E, Kicinski M, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2024. PMID: 39146951. doi:10.1016/S1470-2045(24)00338-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。